Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISLEND-2 weekly oral islatravir/lenacapavir switch study in virologically suppressed adults with HIV-1
2024-514047-28-00Phase 3Authorised
- Sponsor
- Gilead Sciences
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, open-label trial in Human immunodeficiency virus infection type 1 comparing Weekly oral islatravir + lenacapavir switch arm with Standard of care continuation arm (2 arms). Primary endpoint: Proportion of participants with HIV-1 RNA >= 50 copies/mL at Week 48. Planned start Jan 2025; status: authorised.
02
Drugs
islatravirlenacapavir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2024-514047-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514047-28-00.